GleamWall
中文EN

STLN Starling Oncology, Inc.

Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1799191 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.7%
TTM net income YoY5.6%
TTM EPS YoY16.9%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8.9%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-7.4%

Returns

ROE-4,132.2%
ROA-38.7%
ROIC (approx.)-67.7%
Asset turnover2.69x

Leverage & solvency

Liabilities / assets107.5%
Debt / equity—
Current ratio1.68x
Interest coverage-3.90x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-24.8%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$502.73M$393.41M
SG&A expense$105.57M$107.83M
Operating income-$36.08M-$60.12M
Interest expense$11.28M$7.50M
Pretax income-$60.74M-$64.66M
Income tax-$131,000$0
Net income-$60.61M-$64.66M
EBITDA-$29.14M-$53.83M
EPS (basic)-0.54-0.71
EPS (diluted)-0.54-0.71
Weighted avg. shares (diluted)92.39M75.04M
Balance sheet
Cash & equivalents$33.56M$49.67M
Short-term investments—$0
Receivables$59.00M$48.34M
Inventory$16.88M$10.04M
Current assets$112.75M$112.42M
PP&E, net$10.68M$11.89M
Goodwill$7.23M$7.23M
Intangibles$11.02M$14.81M
Total assets$164.66M$172.72M
Current liabilities$70.96M$52.22M
Long-term debt$77.40M$93.13M
Total debt$77.40M$93.13M
Total liabilities$180.38M$169.13M
Shareholders' equity-$15.72M$3.59M
Net debt$43.84M$43.46M
Shares outstanding98.86M75.74M
Cash flow statement
Operating cash flow-$24.59M-$26.54M
Capital expenditure$3.20M$3.79M
Free cash flow-$27.79M-$30.33M
Investing cash flow-$3.07M$46.21M
Financing cash flow$11.56M-$3.49M
Depreciation & amortization$6.94M$6.29M
Stock-based compensation$4.55M$11.15M
Share buybacks—$0

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.